Table 3 Associations between ALC, NLR, their trends and progression-free-survival (PFS) or overall survival (OS) among patients used Eribulin using multivariate cox proportional-hazards analysis

ALC level (Low vs.High [ref]) ^b

 At baseline

1.05 (0.53 – 2.08)

0.888

2.89 (1.33 – 6.26)

0.007*

 At 1-month-test^c

2.26 (1.12 – 4.55)

0.023*

1.33 (0.63 – 2.83)

0.462

 At 3-month-test^c

-

-

2.30 (1.03 – 5.11)

0.042*

 At 6-month-test^c

-

-

1.14 (0.54 – 2.40)

0.728

ALC trends (Decreasing vs. Non-decreasing[ref])

 1-month-test compared with the baseline^d,c

0.82 (0.38 – 1.75)

0.608

0.88 (0.38 – 2.04)

0.768

 3-month-test compared with the baseline^d,c

-

-

2.08 (0.88 – 4.94)

0.095

 6-month-test compared with the baseline^d,c

-

-

0.76 (0.34 – 1.73)

0.515

NLR level (High vs. Low[ref])^e

 At baseline

0.98 (0.50 – 1.91)

0.944

1.59 (0.74 – 3.43)

0.240

 At 1-month-test^c

1.97 (0.96 – 4.27)

0.087

1.45 (0.67 – 3.14)

0.344

 At 3-month-test^c

-

-

2.37 (1.07 – 5.24)

0.033*

 At 6-month-test^c

-

-

2.06 (0.85 – 5.00)

0.109

NLR trends (Non-decreasing vs. non-decreasing [ref])

 1-month-test compared with the baseline^f,c

2.18 (0.92 – 5.18)

0.078

2.15 (0.86 – 5.39)

0.103

 3-month-test compared with the baseline^fc

-

-

2.50 (0.92 – 6.85)

0.074

 6-month-test compared with the baseline^f,c

-

-

6.12 (1.83 – 20.45)

0.003*